

# COLORECTAL CANCER SCREENING

VOLUME 17

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Strategies, which met in Lyon, 14–21 November 2017

LYON, FRANCE - 2019

IARC HANDBOOKS OF  
CANCER PREVENTION

# CONTENTS

---

<b>NOTE TO THE READER</b> .....	1
<b>LIST OF PARTICIPANTS</b> .....	3
<b>WORKING PROCEDURES</b> .....	9
<b>A. GENERAL PRINCIPLES AND PROCEDURES</b> .....	9
1. Background.....	9
2. Scope.....	9
3. Objectives .....	10
4. Meeting participants .....	10
5. Review and evaluation process .....	11
6. Inclusion criteria for data for the <i>Handbooks</i> .....	12
<b>B. SCIENTIFIC REVIEW AND EVALUATION</b> .....	13
1. Descriptive epidemiology and disease characteristics.....	13
2. Screening techniques.....	13
3. Availability and use of screening practices .....	13
4. Efficacy and effectiveness of a screening procedure .....	14
5. Summaries.....	15
6. Evaluation.....	15
References.....	16
<b>GENERAL REMARKS</b> .....	17
<b>LIST OF ABBREVIATIONS</b> .....	21
<b>GLOSSARY</b> .....	23
<b>1. COLORECTAL CANCER</b> .....	27
1.1 Global burden: incidence, mortality, survival, and projections.....	27
1.1.1 Global burden .....	27
1.1.2 International variation and relationship with socioeconomic development.....	27
1.1.3 Survival.....	29
1.1.4 Time trends.....	29
1.1.5 Projections of global burden .....	35

1.2	Classification and natural history	35
1.2.1	Classical adenomas	35
1.2.2	Serrated lesions and polyps	37
1.2.3	Colorectal cancer	38
1.3	Stage at diagnosis, survival, and treatment	38
1.3.1	Stage at diagnosis	38
1.3.2	Survival	39
1.3.3	Treatment	39
1.4	Risk factors and protective factors	41
1.4.1	Lifestyle and environmental factors	42
1.4.2	Host factors	44
1.4.3	Use of medications	45
1.4.4	Etiological differences by subsite	45
	References	46
<b>2.</b>	<b>AVAILABILITY AND USE OF COLORECTAL CANCER SCREENING</b>	<b>51</b>
2.1	Europe	51
2.1.1	Guidelines	52
2.1.2	Policies	52
2.1.3	Programme implementation	56
2.1.4	Participation	57
2.2	Canada and the USA	58
2.2.1	Canada	58
2.2.2	USA	60
2.3	Latin America	61
2.4	Africa	63
2.4.1	North Africa	63
2.4.2	Sub-Saharan Africa	64
2.5	Central, West, and South Asia	64
2.6	East and South-East Asia	65
2.6.1	East Asia	68
2.6.2	South-East Asia	69
2.7	Oceania	70
2.7.1	Australia	71
2.7.2	New Zealand	71
	References	72
<b>3.</b>	<b>STUDIES OF COLORECTAL CANCER SCREENING</b>	<b>79</b>
3.1	Methodological considerations	79
3.1.1	Randomized controlled trials of colorectal cancer screening	79
3.1.2	Observational studies on the preventive effects of colorectal cancer screening	80
3.1.3	Evaluation of the adverse effects of colorectal cancer screening	81
3.1.4	Interval cancers	83
3.1.5	Benefit–harm ratio and cost–effectiveness	83
	References	85
3.2	Stool-based tests for blood	87

---

3.2.1	Techniques	87
3.2.2	Randomized controlled trials	92
3.2.3	Observational studies on preventive effects	97
3.2.4	Adverse effects	109
3.2.5	Benefit–harm ratio of FOBT screening	113
3.2.6	Cost–effectiveness studies	114
	References	127
3.3	Endoscopic methods	137
3.3.1	Techniques	137
3.3.2	Randomized controlled trials	145
3.3.3	Observational studies on preventive effects of endoscopy	153
3.3.4	Adverse effects	163
3.3.5	Benefit–harm ratio	171
3.3.6	Cost–effectiveness studies	176
	References	185
3.4	Comparison of the preventive effects of endoscopic methods and stool-based tests for blood	197
3.4.1	Reduction in colorectal cancer incidence or mortality	197
3.4.2	Detection rates of adenoma and colorectal cancer	197
3.4.3	Cost–effectiveness	203
	References	206
3.5	Computed tomography colonography	209
3.5.1	Technique	209
3.5.2	Preventive effects	212
3.5.3	Adverse effects	217
3.5.4	Benefit–harm ratio and cost–effectiveness	219
	References	220
3.6	Participation in screening for colorectal cancer	225
3.6.1	Determinants of participation in colorectal cancer screening	225
3.6.2	Interventions to increase participation in endoscopy screening	229
3.6.3	Interventions to increase participation in screening with stool-based tests for blood	229
3.6.4	Comparison of participation in two screening methods	231
3.6.5	Informed decision-making	236
	References	236
3.7	Emerging techniques	243
3.7.1	Stool-based tests	243
3.7.2	Capsule colonoscopy	248
3.7.3	Blood-based tests	251
3.7.4	Tests based on other markers	253
	References	255
3.8	Populations at high risk of colorectal cancer	259
3.8.1	Genetic predisposition	259
3.8.2	Family history of colorectal neoplasia	264
3.8.3	Personal history of colorectal neoplasia	270
3.8.4	Medical conditions	276
	References	277

<b>4. SUMMARY</b> .....	283
4.1 Colorectal cancer .....	283
4.2 Colorectal cancer screening worldwide .....	284
4.2.1 Europe .....	284
4.2.2 Canada and the USA .....	284
4.2.3 Latin America .....	284
4.2.4 Africa .....	284
4.2.5 Central, West, and South Asia .....	284
4.2.6 East and South-East Asia .....	285
4.2.7 Oceania .....	285
4.3 Stool-based tests for blood .....	285
4.3.1 Techniques .....	285
4.3.2 Randomized controlled trials of screening with gFOBT .....	285
4.3.3 Observational studies on preventive effects of stool-based tests for blood .....	286
4.3.4 Adverse effects of screening with stool-based tests for blood .....	287
4.3.5 Benefit–harm ratio and cost–effectiveness of screening with stool-based tests for blood .....	287
4.4 Endoscopic methods .....	287
4.4.1 Techniques .....	287
4.4.2 Randomized controlled trials of screening with sigmoidoscopy .....	288
4.4.3 Observational studies on preventive effects of endoscopy .....	288
4.4.4 Adverse effects of screening with endoscopic techniques .....	289
4.4.5 Benefit–harm ratio of screening with endoscopic techniques .....	290
4.5 Comparison of the preventive effects of endoscopic methods and stool-based tests for blood .....	290
4.5.1 Reduction in colorectal cancer incidence or mortality .....	290
4.5.2 Detection rates of adenoma and colorectal cancer .....	290
4.5.3 Cost–effectiveness .....	291
4.6 Computed tomography colonography .....	291
4.7 Participation in screening for colorectal cancer .....	292
4.7.1 Determinants of participation in colorectal cancer screening .....	292
4.7.2 Approaches to increase participation in colorectal cancer screening .....	292
4.7.3 Interventions to increase participation in endoscopy screening .....	292
4.7.4 Interventions to increase participation in screening with stool-based tests for blood .....	293
4.7.5 Comparison of participation in two screening methods .....	293
4.8 Emerging techniques .....	293
4.8.1 Stool-based tests .....	293
4.8.2 Capsule colonoscopy .....	294
4.8.3 Blood-based tests .....	294
4.9 Populations at high risk of colorectal cancer .....	294
4.9.1 Genetic predisposition .....	294
4.9.2 Family history of colorectal neoplasia .....	295
4.9.3 Personal history of colorectal neoplasia .....	295
4.9.4 Medical conditions .....	295

<b>5. EVALUATION</b> .....	297
5.1 Guaiac faecal occult blood test .....	297
5.2 Faecal immunochemical test .....	298
5.3 Flexible sigmoidoscopy .....	298
5.4 Colonoscopy .....	299
5.5 Computed tomography colonography .....	299